Jeffrey Yordon - 20 Jul 2022 Form 4 Insider Report for Athenex, Inc.

Role
COO, and President, Athenex Pharmaceutical Division. Exhibit List: Exhibit 24.1 - Power of Attorney
Signature
/s/Staci Holquist, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Jul 2022
Net transactions value
$0
Form type
4
Filing time
21 Jul 2022, 17:40:39 UTC
Previous filing
05 Aug 2021
Next filing
15 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 237,106 20 Jul 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 20 Jul 2022 Common Stock 150,000 $0.6655 Direct F6
holding ATNXQ Stock Option (Right to Buy) 150,000 20 Jul 2022 Common Stock 150,000 $9.00 Direct
holding ATNXQ Stock Option (Right to Buy) 211,820 20 Jul 2022 Common Stock 211,820 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 100,000 20 Jul 2022 Common Stock 100,000 $17.30 Direct
holding ATNXQ Stock Option (Right to Buy) 100,000 20 Jul 2022 Common Stock 100,000 $13.17 Direct F1
holding ATNXQ Stock Option (Right to Buy) 100,000 20 Jul 2022 Common Stock 100,000 $12.45 Direct F2
holding ATNXQ Stock Option (Right to Buy) 50,000 20 Jul 2022 Common Stock 50,000 $3.80 Direct F3
holding ATNXQ Restricted Stock Units 50,000 20 Jul 2022 Common Stock 50,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on February 28, 2020.
F2 This option vests in four equal annual installments beginning on June 5, 2021.
F3 This option vests in four equal annual installments beginning on August 3, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
F6 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

COO, and President, Athenex Pharmaceutical Division. Exhibit List: Exhibit 24.1 - Power of Attorney